Thoracic Oncology Lab Acquires State-of-the-Art DNA Sequencer

The UCSF Thoracic Oncology Laboratory recently acquired the 5500 Series SOLiDTM , a next-generation DNA sequencer manufactured by Life Technologies Inc. This state-of-the-art sequencer offers a level of precision  previously unattainable, and empowers lab scientists to more deeply probe the underlying molecular biology of myriad cancers: from primary thoracic tumors such as lung cancer, esophageal cancer, and mesothelioma, to metastatic sarcoma, melanoma, colorectal cancer, and breast cancer that has spread to the lung.Insights gained from  this research could lead to more effective treatments, and possibly a cure for these diseases.

The UCSF Thoracic Oncology Program, led by David M. Jablons, M.D., has been at the forefront of groundbreaking laboratory and clinical research, and offers expert and compassionate care through its multidisciplinary team of thoracic specialists. The Thoracic Oncology Program at UCSF would like to acknowledge Gordon and Emily Bankhead and the Kazan, McClain, Abrams, Fernandez, Lyons, Greenwood, Harley & Oberman Foundation for their generous support.